Purpose Imatinib is remarkably effective in treating newly diagnosed patients with chronic
myeloid leukemia (CML) in chronic phase (CP). To date, most of the available data come …

Purpose Long-term clinical outcome data have established imatinib 400 mg/d as standard
front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML) …

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

6506 Background: IM was proven to be superior to IFN+ Ara-C for newly diagnosed patients
(pts) with CML-CP (O'Brien et al, NEJM 2003). 1,106 pts were randomized between June …

Purpose Treatment of chronic-phase (CP) chronic myeloid leukemia (CML) with imatinib 400
mg/d can be unsatisfactory. Optimization of treatment is warranted. Patients and Methods In …

Purpose: Imatinib mesylate is a tyrosine kinase inhibitor with high affinity for the BCR-ABL
fusion protein expressed by the hematopoietic cells in chronic myelogenous leukemia …

Background Imatinib slows development of chronic myeloid leukemia (CML). However,
available information on morbidity and mortality is largely based on sponsored trials …

Purpose To evaluate the safety and efficacy of initial treatment with imatinib mesylate 800
mg/d (400 mg twice daily) versus 400 mg/d in patients with newly diagnosed chronic …

Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …

BACKGROUND: Imatinib mesylate given orally at a daily dose of 400 mg is the standard of
care as initial therapy for patients with chronic myeloid leukemia (CML) in chronic phase …